ABBV

AbbVie Inc.

Healthcare · $466.0B market cap

Share price

$262.82

close of Oct 3, 2026

Fair value

$232.18

Sticker Price

Payback Price

$92.87

buy price

Overpriced

ABBV is Overpriced: at $262.82 it trades 13% above its fair value of $232.18. Its buy price (Payback Price) is $92.87, 65% below today's price. Business quality is strong: 4 of 5 key numbers clear the 10% bar.

How we valued it

Dividend Discount Model. It has paid a dividend for 10+ years in a row, raised it most years, and yields over 2%. For a steady payer like this, the dividend is the best guide to value.

Business quality

4 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth0.6% a year✗

Equity per share growth13.3% a year✓

Sales growth10.3% a year✓

Free cash flow growth11.7% a year✓

Return on invested capital10.5%✓

Follow ABBV

Get notified when it reaches its buy price of $92.87. Free.

Create a free account

Superinvestors

7 of the investors we track hold ABBV. In Q2 2026, 1 trimmed. Who we track

Torray Funds

Torray Funds · as of Q2 2026

$20.8M

82,602 shares

Mairs & Power Funds

Mairs & Power Funds · as of Q2 2026

$11.2M

44,702 shares

David Katz

Matrix Asset Advisors · as of Q2 2026

$9.8M

39,070 shares

Thomas Russo

Gardner Russo & Quinn · as of Q2 2026

$3.1M

12,410 shares

Jensen Investment Management

Jensen Investment Management · as of Q2 2026

$2.8M

11,064 shares

Show all 7 holders

Dodge & Cox Funds

Dodge & Cox Funds · as of Q2 2026

$2.6M

10,393 shares

Bill Nygren

Oakmark Funds · as of Q2 2026

$609K

2,420 shares

Moves in Q2 2026

Trimmed: Torray Funds

Insider activity

Since Jun 30, 2026: no open-market purchases, 1 sale worth $8.2M and 3 other filings (stock awards, tax withholding and similar). Why purchases matter

Sales

Donoghoe Nicholas

EVP, CHIEF BUS/STRAT OFFICER · 2026-08-14

Sold

$8.2M

Other filings

Donoghoe Nicholas

EVP, CHIEF BUS/STRAT OFFICER · 2026-08-14

Option exercise

$2.6M

Quaggin Susan E

director · 2026-06-30

Award

$16K

RAPP EDWARD J

director · 2026-06-30

Award

$34K

About AbbVie Inc.

AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in…

Drug Manufacturers - General

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works